GALECTIN THERAPEUTICS INC — Director's Dealing 2021

Mar 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2021-03-25

Reporting Person: OMENN GILBERT S (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-25	Stock option (right to buy)	$2.11	A	40000	Acquired	2031-03-25	Common Stock (40000)	Direct
2021-03-25	Stock option (right to buy)	$2.11	A	70000	Acquired	2031-03-25	Common Stock (70000)	Direct

Footnotes

F1: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.

F2: Such options vest 100% on March 31, 2022.

F3: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results.